Stock 4AB ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AbbVie Inc. BOERSE MUENCHEN

Equities

4AB

US00287Y1091

Pharmaceuticals

Real-time BOERSE MUENCHEN
Other stock markets
 01:34:17 27/06/2024 pm IST 		5-day change 1st Jan Change
160.9 EUR -0.15% Intraday chart for AbbVie Inc. +1.33% +15.33%
01:05am Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone CI
01:03am U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,30,935 1,89,171 2,39,371 2,85,707 2,73,605 3,02,228 - -
Enterprise Value (EV) 1 1,57,739 2,66,778 3,06,225 3,39,749 3,20,176 3,59,117 3,50,136 3,39,115
P/E ratio 16.8 x 39.4 x 21 x 24.4 x 57 x 29.8 x 23.4 x 20.4 x
Yield 4.96% 4.52% 3.92% 3.53% 3.87% 3.64% 3.8% 3.95%
Capitalization / Revenue 3.94 x 4.13 x 4.27 x 4.92 x 5.04 x 5.48 x 5.19 x 4.85 x
EV / Revenue 4.74 x 5.83 x 5.46 x 5.85 x 5.89 x 6.51 x 6.02 x 5.44 x
EV / EBITDA 8.89 x 11.8 x 10.6 x 11 x 12.5 x 13.6 x 12.3 x 10.9 x
EV / FCF 12.4 x 15.9 x 13.9 x 14 x 14.5 x 18.8 x 14.2 x 12.7 x
FCF Yield 8.1% 6.29% 7.18% 7.14% 6.89% 5.32% 7.05% 7.85%
Price to Book -16.1 x 13.7 x 15.5 x 16.6 x 26.5 x 32.7 x 29.4 x 24.8 x
Nbr of stocks (in thousands) 14,78,821 17,65,474 17,67,880 17,67,880 17,65,537 17,65,868 - -
Reference price 2 88.54 107.2 135.4 161.6 155.0 171.2 171.2 171.2
Announcement Date 07/02/20 03/02/21 02/02/22 09/02/23 02/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,266 45,784 56,122 58,054 54,318 55,199 58,192 62,358
EBITDA 1 17,747 22,642 29,018 30,961 25,545 26,357 28,427 31,209
EBIT 1 15,730 21,976 28,215 30,183 24,793 25,594 27,650 30,437
Operating Margin 47.29% 48% 50.27% 51.99% 45.64% 46.37% 47.51% 48.81%
Earnings before Tax (EBT) 1 8,426 3,398 12,989 13,477 6,250 12,004 13,864 15,857
Net income 1 7,882 4,616 11,542 11,836 4,863 8,604 11,435 13,567
Net margin 23.69% 10.08% 20.57% 20.39% 8.95% 15.59% 19.65% 21.76%
EPS 2 5.280 2.720 6.450 6.630 2.720 5.734 7.310 8.410
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,094 24,672 26,629
FCF margin 38.39% 36.67% 39.18% 41.77% 40.62% 34.59% 42.4% 42.7%
FCF Conversion (EBITDA) 71.97% 74.15% 75.78% 78.32% 86.37% 72.45% 86.79% 85.32%
FCF Conversion (Net income) 162.04% 363.73% 190.52% 204.87% 453.67% 221.94% 215.76% 196.28%
Dividend per Share 2 4.390 4.840 5.310 5.710 5.990 6.232 6.503 6.759
Announcement Date 07/02/20 03/02/21 02/02/22 09/02/23 02/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 14,886 13,538 14,583 14,812 15,121 12,225 13,865 13,927 14,301 12,310 14,016 14,196 14,729 13,208 14,374
EBITDA 1 7,506 7,156 7,643 8,090 8,072 5,682 6,710 6,706 6,447 - 7,100 6,877 7,049 - -
EBIT 1 7,333 6,958 7,440 7,909 7,876 5,503 6,520 6,510 6,260 5,195 6,899 6,721 6,826 6,631 7,053
Operating Margin 49.26% 51.4% 51.02% 53.4% 52.09% 45.01% 47.02% 46.74% 43.77% 42.2% 49.22% 47.34% 46.34% 50.2% 49.07%
Earnings before Tax (EBT) 1 - - - - - 475 2,610 1,953 1,212 1,755 3,504 3,346 3,397 - -
Net income 1 4,044 4,490 924 3,949 2,473 239 2,024 1,778 822 1,369 2,643 2,437 2,393 2,477 2,834
Net margin 27.17% 33.17% 6.34% 26.66% 16.35% 1.96% 14.6% 12.77% 5.75% 11.12% 18.85% 17.17% 16.25% 18.75% 19.72%
EPS 2 2.260 2.510 0.5100 2.210 1.380 0.1300 1.140 1.000 0.4600 0.7700 1.796 1.576 1.670 1.390 1.590
Dividend per Share 2 1.410 1.410 1.410 1.410 1.480 1.480 1.480 1.480 1.550 - 1.549 1.549 1.549 1.605 1.605
Announcement Date 02/02/22 29/04/22 29/07/22 28/10/22 09/02/23 27/04/23 27/07/23 27/10/23 02/02/24 26/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 26,804 77,607 66,854 54,042 46,571 56,889 47,908 36,886
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.51 x 3.428 x 2.304 x 1.745 x 1.823 x 2.158 x 1.685 x 1.182 x
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,094 24,672 26,629
ROE (net income / shareholders' equity) -160% 188% 159% 151% 143% 177% 191% 198%
ROA (Net income/ Total Assets) 10.6% 3.85% 15.3% 17.2% 14.5% 9.36% 10.7% 13.2%
Assets 1 74,234 1,19,840 75,543 68,651 33,641 91,901 1,07,209 1,02,913
Book Value Per Share 2 -5.510 7.830 8.710 9.740 5.840 5.240 5.830 6.890
Cash Flow per Share 2 8.980 10.50 12.80 14.00 12.90 13.60 15.30 13.70
Capex 1 552 798 787 695 777 816 836 867
Capex / Sales 1.66% 1.74% 1.4% 1.2% 1.43% 1.48% 1.44% 1.39%
Announcement Date 07/02/20 03/02/21 02/02/22 09/02/23 02/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.2 USD
Average target price
183.2 USD
Spread / Average Target
+7.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 81TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.79% 64TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 33TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.00% 25TCr
ROCHE HOLDING AG Stock Roche Holding AG
+2.62% 22TCr
NOVARTIS AG Stock Novartis AG
+12.76% 22TCr
AMGEN INC. Stock Amgen Inc.
+8.61% 17TCr
PFIZER, INC. Stock Pfizer, Inc.
-4.76% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. 4AB Stock
  5. Financials AbbVie Inc.